(secondQuint)A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD.

 Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common childhood disorders and can continue through adolescence and adulthood.

 Symptoms include difficulty staying focused and paying attention, difficulty controlling behavior and hyperactivity (over-activity).

 This multicenter study will utilize a 6-week open label, treatment optimization phase followed by a double-blind, placebo-controlled, 1-week randomized, parallel-group test period designed to assess the safety and efficacy of HLD200 treatment in pediatric subjects with ADHD.

.

 A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD@highlight

This study will examine the efficacy and safety of HLD200 (methylphenidate) in patients age 6-12 years with ADHD.

 This study has a 6-week dose optimization period followed by a one week double blind randomization assessment.

